文献速递胸部肿瘤

致癌驱动基因突变在多原发肺癌分期中的应用:单中心经验

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience.
PubMed 文献 · J Thorac Oncol · 2017-06-21

该单中心研究先比较45例原发瘤与转移瘤的分子驱动结果,再对69例共154个同时或异时肺癌比较病理与驱动突变,按临床、病理和分子结果赋予最高T或M分期。结果显示驱动突变在原发瘤与转移瘤间一致率高,多叶结节以多原发肺癌为主,总生存高于相应最高T或M分期的预期。

要点

  • 原发瘤与转移瘤间EGFR、KRAS、BRAF和ALK突变一致率为96%。
  • 多叶受累结节中81.5%为多原发肺癌,7.4%为肺内转移。
  • 单叶结节中36%为多原发肺癌,40%为肺内转移,24%分子无信息。

核心结论

  • 致癌驱动突变在原发瘤与转移瘤之间一致。
  • 多原发肺癌最大比例见于多叶肿瘤,但单叶结节和异时肿瘤中也有相当比例的多原发肺癌。
  • 总生存高于相应最高T或M分期的预期,支持多原发肺癌的高频率。

研究设计与样本

  • 单中心研究,队列1比较45例原发瘤与其转移瘤的分子驱动结果。
  • 队列2纳入69例共154个同时或异时肺癌,比较病理发现与致癌驱动突变,并按临床、组织病理和分子结果赋予每例最高潜在T或M分期。

主要发现

  • 队列1中EGFR、KRAS、BRAF和ALK受体酪氨酸激酶基因(ALK)突变的一致率为96%。
  • 队列2中多个同叶结节36%为多原发肺癌,40%为肺内转移,24%分子无信息。
  • 多叶受累结节中81.5%为多原发肺癌,7.4%为肺内转移,11%无信息。
  • 异时肿瘤中52.9%为多原发肺癌。
  • 有随访数据的患者总生存2年为100%,3年为95%,4年为80%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The staging of multiple pulmonary adenocarcinomas requires the distinction of intrapulmonary metastasis (IPM) from multiple primary lung cancers (MPLCs). This can be challenging in some patients, and the addition of data from oncogenic driver mutations in these tumors may be helpful in this determination. METHODS: As a proof of principle, molecular driver results from primary tumors and their metastases in 45 patients were compared (cohort 1). Then, 69 patients with a total of 154 synchronous or metachronous lung carcinomas were identified, and the pathologic findings were compared with oncogenic driver mutation. Each patient was assigned a highest potential T or M category on the basis of clinical, histopathologic, and molecular findings (cohort 2). RESULTS: The concordance rate of EGFR, KRAS, BRAF, and ALK receptor tyrosine kinase gene (ALK) mutations was 96% in cohort 1. In cohort 2, 36% of multiple same-lobe nodules were MPLCs, 40% were IPM, and 24% were noninformative by molecular findings. Of nodules with multiple lobe involvement, 81.5% were MPLCs and 7.4% were IPM, with 11% noninformative. Of metachronous tumors, 52.9% were MPLCs. Overall survival was 100% at 2 years, 95% at 3 years, and 80% at 4 years in patients with available follow-up. CONCLUSIONS: Oncogenic driver mutations are concordant between primary tumors and metastasis. The largest proportion of MPLCs was seen in tumors of multiple lobes, but with a substantial proportion of MPLCs among single-lobe nodules and with metachronous tumors. Overall survival was higher than expected for the respective highest T or M category, which is in support of the high frequency of MPLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Asmar R, Sonett JR, Singh G, et al. Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience. J Thorac Oncol. 2017. PMID: 28647671. doi:10.1016/j.jtho.2017.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。